Johnson & Johnson (J&J) has reported the latest data confirming the robust and durable protection provided by its Janssen Covid-19 vaccine.
The single-shot vaccine is authorised under a US Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for active immunisation to prevent Covid-19 in people aged 18 years and above.
According to results from the largest real-world evidence study of the vaccine reported so far in the US, stable vaccine efficiency of 79% for Covid-19-associated infections and 81% for hospitalisations linked to the disease were observed.
The study conducted from March to July comprised 390,000 individuals who received the vaccine analysed against nearly 1.52 million unvaccinated people.
No indication of a decline in effectiveness over the study period was reported, including when the Delta variant of SARS-CoV-2 was dominant in the US.
Furthermore, these results are in line with the Phase III ENSEMBLE clinical trial, in which the vaccine offered robust protection against severe/critical disease and mortality at a minimum of 28 days after the vaccination.
Overall efficacy of 75% against severe/critical Covid-19 was observed across all age groups and all countries included in the trial.
The efficacy of 74% against severe/critical Covid-19 was reported in the US while 89% and 83% efficacies against hospitalisation and Covid-19-associated mortality, respectively, were noted.
Leave a Reply